06.03.13
Goodwin Biotechnology, Inc. (GBI) was awarded a sub-contract from Emergent BioSolutions to conduct an early stage proof-of-concept feasibility process development to concentrate AVA filtrate for storage before the downstream process for BioThrax (Anthrax Vaccine Adsorbed). BioThrax is the only vaccine licensed by the FDA for the protection against anthrax disease.
"We're excited about the opportunity to contribute our protein purification as well as processing experience and expertise which have been developed and refined over the last 20 years," said Muctarr Sesay, Ph.D., vice president of process development at GBI. "Our goal is to develop process parameters that are amenable to routine GMP production and large-scale manufacturing in an effort to contribute to the production of BioThrax at large scale."
Heidi Nielsen, process development engineer for the Biodefense Division of Emergent BioSolutions said, "This phase of process development is critical to our project. We chose to work with Goodwin Biotechnology based on their Quality Systems and experience with large scale, GMP-compliant protein purification and processing."
"We're excited about the opportunity to contribute our protein purification as well as processing experience and expertise which have been developed and refined over the last 20 years," said Muctarr Sesay, Ph.D., vice president of process development at GBI. "Our goal is to develop process parameters that are amenable to routine GMP production and large-scale manufacturing in an effort to contribute to the production of BioThrax at large scale."
Heidi Nielsen, process development engineer for the Biodefense Division of Emergent BioSolutions said, "This phase of process development is critical to our project. We chose to work with Goodwin Biotechnology based on their Quality Systems and experience with large scale, GMP-compliant protein purification and processing."